JOSD2 inhibits nuclear localisation by reducing the lysine 433 acetylation of PKM2 in acute myeloid leukaemia (AML), thereby decreasing downstream gene expression and ultimately slowing AML progression.243. This evidence concerns the gene JOSD2 and acute myeloid leukemia.